What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Detailed price information for Goldman Sachs Group (GS-N) from The Globe and Mail including charting and trades.

Lilly makes tirzepatide, sold under the name Zepbound ... and moves Amazon has made to revamp its cost structure in recent years should set it on the right earnings path in the coming months ...

Starboard builds 7.7% stake in chipmaker Qorvo, WSJ reports Technologycategory· January 17, 2025 The nation's three largest pharmacy ... claiming to contain tirzepatide, the main ingredient ...

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, but users say the benefits are worth the effort.

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

JRPGs like Tales of Berseria expertly use the three-act structure for satisfying character arcs and plots. Xenoblade Chronicles 2 stands out for its effective use of the three-act structure ...

Enter GetSimpli Oral Tirzepatide, a revolutionary product ... interfere with the active ingredients while providing necessary structure and consistency to the product. By maintaining a clean ...